TherapeuticsMD, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431
Mailing Address 951 YAMATO ROAD, SUITE 220, BOCA RATON, FL, 33431
Phone 561-961-1900
Fiscal Year End 1231
EIN 870233535
Financial Overview
FY2025
$11.45M
Total Liabilities
$29.29M
Stockholders' Equity
$-0.05
EPS
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 8-K Current report of material events | January 21, 2026 | View on SEC |
| 4 Insider stock transaction report | December 29, 2025 | View on SEC |
| 8-K Current report of material events | December 16, 2025 | View on SEC |
| 8-K Current report of material events | November 13, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 12, 2025 | View on SEC |
| 4 Insider stock transaction report | November 5, 2025 | View on SEC |
| 4 Insider stock transaction report | November 5, 2025 | View on SEC |
| 4 Insider stock transaction report | November 5, 2025 | View on SEC |
Annual Reports
10-K March 30, 2026
- Transitioned to a lean pharmaceutical royalty-collection business model.
- Outsourced all marketing and sales operations to partners like Mayne Pharma and Theramex.
Insider Trading
BUY 1 insiders
1 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.